Aptevo Therapeutics Forges Radiotherapeutic Partnership with Niowave, Secures $0.5M Investment Above Market Price
APVO sits 26% above its 52-week low of $3.8.
Summary
Aptevo Therapeutics has entered into a strategic radiotherapeutic collaboration with Niowave, which includes cross-licensing and a contingent supply agreement for Actinium-225. Concurrently, Niowave invested $0.5 million in Aptevo through a private placement at $5.075 per share, a premium to the current market price, and received warrants at $8.00. This follows an 8-K filing today detailing the collaboration and comes after recent positive clinical data announcements and a reiterated going concern warning. The partnership expands Aptevo's pipeline into a new strategic area, and the investment, though modest, provides capital and signals confidence from a key partner.
At the time of this announcement, APVO was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $3.80 to $235.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.